Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ACE393

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Campylobacter jejuni · developed by Lumen Bioscience

Phase 2 Most advanced trial (none active)
1 Registered trials

What is ACE393?

ACE393 is a Campylobacter jejuni vaccine given as two intramuscular injections at day 0 and day 21. It is studied for prevention of Campylobacter infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Campylobacter jejuni
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Campylobacter jejuni (antigen)
Mechanism
Immune activation, directed at Campylobacter jejuni
Therapy area
Infectious disease
Developer
Lumen Bioscience, Inc.
In trials of
FULC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00859716 Phase 2 Campylobacter Infection Unknown FULC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Campylobacter Infection

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.